ALIDHE: A PHASE 3B STUDY ASSESSING IVOSIDENIB + AZACITIDINE IN ADULTS WITH NEWLY DIAGNOSED MIDH1 ACUTE MYELOID LEUKAEMIA WHO ARE INELIGIBLE FOR INTENSIVE INDUCTION CHEMOTHERAPY (SIE 2026) - Oct 6, 2026 - Abstract #DP081; Pres time: Sep 21, 2026; 07:00 PM - 08:00 PM; Location: AREA POSTER; P3 | "These data from the ongoing ALIDHE study confirm the IVO+AZA efficacy and safety pro- file seen in the pivotal AGILE study."
Clinical • P3 data • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • IDH1
|
|
A. Curti1; E. Borlenghi2; F. Mannelli3; M. B. Giannini4; M. Frigeni5; C. Skert6; A. Isidori7; N. S. Fracchiolla8; M. P. Martelli9; M. Tiribelli10; P. Vyas11,12; C. Recher13; H. Döhner14; D. Camanho15; A. Sullivan16; V. Lacoste17; M. Romagnoli15; B. Cognet17; C. Dinardo18; S. Vives19; A. Venditti20
|